Controlled Clinical Trials
DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 24, Number 1, 2003

Contents

Call for papers 1

Preface 2

Original articles

MICHAEL A. PROSCHAN, QING LIU, SALLY HUNSBERGER
Practical midcourse sample size modification in clinical trials 4

Y.H. JOSHUA CHEN, DAVID L. DEMETS, K.K. GORDON LAN
Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis 16

NEAL L. ODEN, DALE L. PHELPS, ON BEHALF OF THE STOP-ROP MULTICENTER STUDY GROUP
Statistical issues related to early closure of STOP-ROP, a group-sequential trial 28

DEBORAH J. BOWEN, MARK THORNQUIST, KAREN ANDERSON, MATT BARNETT, CORINNE POWELL, GARY GOODMAN, GILBERT OMENN
Stopping the active intervention: CARET 39

LETICIA DELGADO-HERRERA, DAN ANBAR
A model for the interim analysis process: a case study 51

Invited papers

KEITH WHEATLEY, DAVID CLAYTON
Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization 66

JOSEPH F. COLLINS
Data and safety monitoring board issues raised in the VA Status Epilepticus Study 71

MARIO CHEN-MOK, SHRIKANT I. BANGDIWALA, ROSALIE DOMINIK, MELISSA HAYS, BELINDA IRSULA, DAVID C. SOKAL
Termination of a randomized controlled trial of two vasectomy techniques 78

DAVID W. HILLMAN, THOMAS A. LOUIS
DSMB case study: decision making when a similar clinical trial is stopped early 85

ADELE M. KAPLAN GILPIN, JANET T. HOLBROOK, DOUGLAS A. JABS, CURTIS L. MEINERT, FOR THE STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP
Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial 92

DAVID SCHEIFELE, BERNARD DUVAL, GASTON DE SERRES, DANUTA M. SKOWRONSKI
Unique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications 99

Book review 105

List of reviewers 107

Volume 24, Number 2, 2003

Contents

Call for papers 109

Original articles

SAY-BENG TAN, Y.-F. ALEXANDER CHUNG, BEE-CHOO TAI, YIN-BUN CHEUNG, DAVID MACHIN
Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma 110

A. GREGORY DIRIENZO, VICTOR DEGRUTTOLA
Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clincial Trials Group Study A5142 122

HONGYU JIANG, RICK CHAPPELL, JASON P. FINE
Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout 135

SUE-JANE WANG, H.M. JAMES HUNG
Assessing treatment efficacy in noninferiority trials 147

VANCE W. BERGER, AZADEH REZVANI, VANESSA A. MAKAREWICZ
Direct effect on validity of response run-in selection in clinical trails 156

JITENDRA GANJU, DEVAN V. MEHROTRA
Stratified experiments reexamined with emphasis on multicenter trials 167

ARTHUR A. STONE, SAUL SHIFFMAN, JOSEPH E. SCHWARTZ, JOAN E. BRODERICK, MICHAEL R. HUFFORD
Patient compliance with paper and electronic diaries 182

Book reviews 200

Design papers

WENDY DEMARK-WAHNEFRIED, MIRIAM C. MOREY, ELIZABETH C. CLIPP, CARL F. PIEPER, DENISE CLUTTER SNYDER, RICHARD SLOANE, HARVEY J. COHEN
Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors 206

OLIVER M. BAUTISTA, JOHN W. KUSEK, LEROY M. NYBERG JR., JOHN D. MCCONNELL, RAYMOND P. BAIN, GARY MILLER, E. DAVID CRAWFORD, STEVEN A. KAPLAN, STEPHEN A. SIHELNIK, MICHAEL K. BRAWER, HEBERT LEPOR, FOR THE MTOPS RESEARCH GROUP
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial 224

Volume 24, Number 3, 2003

Contents

Original articles

WILLIAM BURMAN, PETER BREESE, STEPHEN WEIS, NAOMI BOCK, JOHN BERNARDO, ANDREW VERNON, AND THE TUBERCULOSIS TRIALS CONSORTIUM
The effects of local review on informed consent documents from a multicenter clinical trials consortium 245

ROBERT M. CALIFF, MICHAEL A. MORSE, JANET WITTES, STEVEN N. GOODMAN, DANIEL K. NELSON, DAVID L. DEMETS, R. PETER IAFRATE, JEREMY SUGARMAN
Toward protecting the safety of participants in clinical trials 256

NICOLA MILLS, JENNY L. DONOVAN, MONICA SMITH, ANN JACOBY, DAVID E. NEAL, FREDDIE C. HAMDY
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study 272

CHENGJIE XIONG, YAN YAN, MING JI
Sample sizes for comparing means of two lifetime distributions with type II censored data: application in an aging intervention study 283

STEVEN E. FELDON, ROBERTA W. SCHERER, FRANK J. HOOPER, SHALOM KELMAN, ROBERT S. BAKER, ROBERT J. GRANADIER, GREGORY S. KOSMORSKY, STUART R. SEIFF, KAY DICKERSIN, FOR THE ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL RESEARCH GROUP
Surgical quality assurance in the Ischemic Optic Neuropathy Decompression Trial (IONDT) 294

DAVID JARJOURA
Crossing controls to treatment in repeated-measures trials 306

CHRISTOPHER H. SCHMID, MARCIA LANDA, TAZEEN H. JAFAR, IOANNIS GIATRAS, TAUQEER KARIM, MANOJ REDDY, PAUL C. STARK, ANDREW S. LEVEY, FOR THE ANGIOTENSIN-CONVERTING ENZYME INHIBITION IN PROGRESSIVE RENAL DISEASE (AIPRD) STUDY GROUP
Constructing a database of individual clinical trials for longitudinal analysis 324

AL HALLSTROM, LAWRENCE FRIEDMAN, PABLO DENES, CARLOS RIZO-PATRON, MARY MORRIS, AND THE CAST AND AVID INVESTIGATORS
Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST) and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID) 341

Book review 353

Volume 24, Number 3S, 2003
Supplement

Contents

Letter from the President 1S

Calendar of Program 7S

Abstracts: Third Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics 43S
Author Index 241S

Volume 24, Number 4, 2003

Contents

Original articles

MITHAT GÖNEN
Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer 355

MAN-LAI TANG
Matched-pair noninferiority trials using rate ratio: a comparison of current methods and sample size refinement 364

JAMES X. SONG, JAMES T. WASSELL
Sample size for K 2 × 2 tables in equivalence studies using Cochran's statistic 378

REBECCA HOLMAN, CEES A.W. GLAS, ROB J. DE HAAN
Power analysis in randomized clinical trials based on item response theory 390

LAURENCE S. MAGDER
Simple approaches to assess the possible impact of missing outcome information on estimates of risk ratios, odds ratios, and risk differences 411

MARIE JACKSON, NANCY BERMAN, MARGARET HUBER, LINDA SNETSELAAR, IRIS GRANEK, KATHRYN BOE, CAROLE MILAS, JILL SPIVAK, ROWAN T. CHLEBOWSKI
Research staff turnover and participant adherence in the Women's Health Initiative 422

Letter to the editor 436

Book review 440

Design papers

THE BENEDICT GROUP
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics 442

GARY D. MILLER, W. JACK REJESKI, JEFF D. WILLIAMSON, TIMOTHY MORGAN, MARY ANN SEVICK, RICHARD F. LOESER, WALT H. ETTINGER, STEPHEN P. MESSIER FOR THE ADAPT INVESTIGATORS
The Arthritis, Diet and Activity Promotion Trial (ADAPT): design, rationale, and baseline results 462

TASSOS C. KYRIAKIDES, ABDEL BABIKER, JOEL SINGER, WILLIAM CAMERON, MARTIN T. SCHECHTER, MARK HOLODNIY, SHELDON T. BROWN, MIKE YOULE, BRIAN GAZZARD ON BEHALF OF THE OPTIMA STUDY TEAM
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial 481

Volume 24, Number 5, 2003

Contents

Original articles

RAYMOND Q. MIGRINO, ERIC J. TOPOL
A matter of life and death? The Heart Protection Study and protection of clinical trial participants 501

THEODORE G. KARRISON, DEZHENG HUO, RICK CHAPPELL
A group sequential, response-adaptive design for randomized clinical trials 506

CAROLINE C. MORGAN
Estimation following group-sequential response-adaptive clinical trials 523

LUKE B. CONNELLY
Balancing the number and size of sites: an economic approach to the optimal design of cluster samples 544

MIYUKI KAWADO, SHIRO HINOTSU, YUTAKA MATSUYAMA, TAKUHIRO YAMAGUCHI, SHUJI HASHIMOTO, YASUO OHASHI
A comparison of error detection rates between the reading aloud method and the double data entry method 560

MIKE R. SATHER, DENNIS W. RAISCH, CLAIR M. HAAKENSON, JULIA M. BUCKELEW, JOHN R. FEUSSNER
Promoting good clinical practices in the conduct of clinical trials: experiences in the Department of Veterans Affairs Cooperative Studies Program 570

Commentary

SUSAN S. ELLENBERG
Are all monitoring boundaries equally ethical? 585

Book review 589

Design papers

KAY DICKERSIN, MALCOLM MUNRO, PATRICIA LANGENBERG, ROBERTA SCHERER, KEVIN D. FRICK, ANNE M. WEBER, ALAN JOHNS, JEFFREY F. PEIPERT, MELISSA CLARK, AND THE STOP-DUB RESEARCH GROUP
Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): design and methods 591

THE LOOK AHEAD RESEARCH GROUP
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes 610

LINDA BRUBAKER, GEOFF CUNDIFF, PAUL FINE, INGRID NYGAARD, HOLLY RICHTER, ANTHONY VISCO, HALINA ZYCZYNSKI, MORTON B. BROWN, ANNE WEBER, FOR THE PELVIC FLOOR DISORDERS NETWORK
A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods 629

J.M. STEPHENSON, A. OAKLEY, A.M. JOHNSON, S. FORREST, V. STRANGE, S. CHARLESTON, S. BLACK, A. COPAS, A. PETRUCKEVITCH, A. BABIKER
A school-based randomized controlled trial of peer-led sex education in England 643

Announcements 659

Program 2003 Errata 665

Volume 24, Number 6, 2003

Contents

Preface 667

Original articles

THOMAS M. BRAUN, JOHN E. LEVINE, JAMES L.M. FERRARA
Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM 669

KEVIN J. CARROLL
On the use and utility of the Weibull model in the analysis of survival data 682

PHILIP P. BREITFELD, FRED ULLRICH, JAMES ANDERSON, WILLIAM M. CRIST
Web-based decision support for clinical trial eligibility determination in an international clinical trials network 702

JEFFREY J. WALLINE, LISA A. JONES, DONALD O. MUTTI, KARLA ZADNIK
Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study 711

Invited papers

SHEILA SPRAGUE, PAMELA LEECE, MOHIT BHANDARI, PAUL TORNETTA, EMIL SCHEMITSCH, MARC F. SWINOTKOWSKI, ON BEHALF OF THE S.P.R.I.N.T. INVESTIGATORS
Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery 719

JOSEPH F. COLLINS, CINDY L. HOWELL, R. ANNE HORNEY FOR THE DIGITALIS INVESTIGATION GROUP (DIG) INVESTIGATORS
Determination of vital status at the end of the DIG trial 726

ANDREW J. VICKERS, ROB MCCARNEY
Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year 731

Design papers

CHRISTIAN C. APFEL, KARI KORTTILA, MONA ABDALLA, ANDREAS BIEDLER, PETER KRANKE, STUART J. POCOCK, N. ROEWER
An International Multicenter Protocol to Assess the single and combined benefits of antiemetic interventions in a Controlled clinical Trial of a $2 \times 2 \times 2 \times 2 \times 2 \times 2$ factorial design (IMPACT) 736

MICHIEL L. BOTS, GREGORY W. EVANS, WARD RILEY, RUDY MEIJER, KAREN H. MCBRIDE, ELECTRA D. PASKETT, FRANS A. HELMOND, DIEDERICK E. GROBBEE, FOR THE OPAL INVESTIGATORS
The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics 752

ROB BEANLANDS, GRAHAM NICHOL, TERRENCE D. RUDDY, ROBERT A. DEKEMP, PAUL HENDRY, DENNIS HUMEN, NORMAND RACINE, HEATHER ROSS, FRANCOIS BENARD, GEOFFREY COATES, ROBERT M. IWANOCHKO, ERNEST FALLEN, GEORGE WELLS, AND THE PARR-2 INVESTIGATORS
Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods 776

THE CHILDREN'S AMALGAM TRIAL STUDY GROUP
The Children's Amalgam Trial: design and methods 795

THE CTNS STUDY GROUP
The Italian-American Clinical Trial of Nutritional Supplements and Age-Related Cataract (CTNS): design implications. CTNS report no. 1 815

List of Reviewers 831

Volume 24 Author Index 833

Volume 24 Subject Index 836

Volume Contents 845

Volume 24, Number 6S, 2003
Supplement

Contents

List of contributors 267S

JOSEPH F. COLLINS, DEBRA EGAN, SALIM YUSUF, REKHA GARG, WILLIAM O. WILLIFORD, NANCY GELLER ON BEHALF OF THE DIG INVESTIGATORS
Overview of the DIG trial 270S

WILLIAM O. WILLIFORD, JOSEPH F. COLLINS, ANNE HORNEY, GAIL KIRK, FRANCES MCSHERRY, ELIZABETH SPENCE, SUSAN STINNETT, CINDY L. HOWELL, REKHA GARG, DEBRA EGAN, SALIM YUSUF ON BEHALF OF THE DIG INVESTIGATORS
The role of the data coordinating center in the DIG trial 278S

CAROL L. FYE, WILLIAM H. GAGNE, DENNIS W. RAISCH, MARK S. JONES, MIKE R. SATHER, SANDRA L. BUCHANAN, FRANCES R. CHACON, REKHA GARG, SALIM YUSUF, WILLIAM O. WILLIFORD ON BEHALF OF THE DIG INVESTIGATORS
The role of the pharmacy coordinating center in the DIG trial 290S

JOSEPH F. COLLINS, SYLVIA MARTIN, ELEANOR KENT, CONNIE LIUNI, REKHA GARG, DEBRA EGAN ON BEHALF OF THE DIG INVESTIGATORS
The use of regional coordinating centers in large clinical trials: the DIG trial 299S

JOSEPH F. COLLINS, REKHA GARG, KOON K. TEO, WILLIAM O. WILLIFORD, CINDY L. HOWELL ON BEHALF OF THE DIG INVESTIGATORS
The role of the data coordinating center in the IRB review and approval process: the DIG trial experience 307S

DEBRA EGAN, NANCY GELLER, SALIM YUSUF, REKHA GARG, JOSEPH F. COLLINS, JAMES MATHEW, EDWARD PHILBIN ON BEHALF OF THE DIG INVESTIGATORS
Lessons learned from the DIG trial 317S

Appendix 328S